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Abstract
Purpose The immune checkpoint inhibitors (ICIs) have resulted in subgroups of patients with metastatic melanoma achieving
high-quality durable responses.Metastatic melanoma survivors are a new population in the era of cancer survivorship. The aim of
this study was to evaluate metastatic melanoma survivors in terms of health-related quality of life (HRQoL), immune-related
adverse events (irAEs) and exposure to immunosuppressive agents in a large single centre in the UK.
Methods We defined the survivor population as patients with a diagnosis of metastatic melanoma who achieved a durable
response to an ICI and had been followed-up for a minimum of 12 months from initiation of ICI without disease progression.
HRQoL was assessed using SF-36. Electronic health records were accessed to collect data on demographics, treatments, irAEs
and survival. HRQoL data was compared with two norm-based datasets.
Results Eighty-four metastatic melanoma survivors were eligible and 87% (N = 73) completed the SF-36. ICI-related toxicity of
any grade occurred in 92% of patients and 43% had experienced a grade 3 or 4 toxicity. Almost half (49%) of the patients required
steroids for the treatment of ICI-related toxicity, whilst 14% required treatment with an immunosuppressive agent beyond
steroids.
Melanoma survivors had statistically significant lower HRQoL scores with regard to physical, social and physical role
functioning and general health compared with the normative population. There was a trend towards inferior scores in patients
with previous exposure to ipilimumab compared with those never exposed to ipilimumab.
Conclusions Our results show that metastatic melanoma survivors have potentially experienced significant ICI-related toxicity
and experience significant impairments in specific HRQoL domains. Future service planning is required to meet this population’s
unique survivorship needs.
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Background
The introduction of the immune checkpoint inhibitors (ICIs)
has transformed the therapeutic arena in metastatic melanoma
such that subsets of patients now have the potential to achieve
high-quality durable responses and in some cases cure can be
achieved. This has translated into an unprecedented number of
patients now living with a diagnosis of metastatic melanoma.
Oncology clinics worldwide are faced with a new population
of patients, the ‘metastatic melanoma survivors’. Many of the
principles and applications of cancer survivorship that are
common across all survivor populations are relevant to the
metastatic melanoma survivors [1, 2]. However, at a time
when exciting new therapies are replacing older therapies rec-
ognition of tumour-specific and treatment-specific issues that
limit the survivor’s return to full physical and psychosocial
functioning are necessary to achieve optimal cancer survivor
care.
Metastatic melanoma survivors can encounter obstacles in
restoration and maintenance in physical domains of health-
related quality of life (HRQoL) due to toxicity from ICIs.
The immune checkpoints are inhibitory signals that form part
of a large network of signalling pathways that act as gate-
keepers to the activation of the immune system and regulate
the magnitude and duration of the immune response. ICIs are
often referred to as ‘the brakes of the immune system’.
Removing the ‘brakes’ has the potential to unleash the effec-
tors of the immune system in an unrestrained manner and
result in a class of inflammatory adverse events that are unique
to ICIs [3, 4]. Frequency of toxicity differs between ICIs.
Common toxicities include dermatological toxicity, colitis
and hepatitis with rarer toxicities including myocarditis and
neurological toxicity [5]. These physical adverse events have
the potential to cause significant and persistent morbidity
which can occur during therapy but also post-discontinuation.
The mainstay of treatment for immune-related adverse events
(irAEs) is corticosteroids. Immunomodulatory agents such as
infliximab andmycophenolate are utilised in steroid refractory
or resistant cases. These therapies can cause toxicities in their
own right ranging from issues surrounding glucose tolerance
and bone health to viral reactivation and hepatotoxicity. Any
survivorship pathway for patients treated with an ICI, which
represents the majority of metastatic melanoma survivors,
must account for the direct and indirect physical issues
irAEs provoke.
The metastatic melanoma survivor will also encounter psy-
chosocial obstacles to restoration of health including uncer-
tainty regarding response to treatment, fear of disease progres-
sion or recurrence, negative impact on relationships, work and
financial concerns and dealing with unexpected effects of
treatment in daily life [6] [7]. The first patient with metastatic
melanoma was treated with ipilimumab in a phase 1 trial in
2000. In 2011, ipilimumab was the first ICI to be approved by
the FDA and subsequently the EMA for metastatic melanoma.
The PD-1 inhibitors nivolumab and pembrolizumab were ap-
proved for metastatic melanoma in 2014. This was followed
by the approval of the combination of ipilimumab and
nivolumab in 2015. Our experience with ICIs in clinical prac-
tice is thus relatively limited. Clinical trials do not reflect real-
world populations. In a recent report, Donia et al. applied the
eligibility criteria from the pivotal phase III trials of ICIs in
metastatic melanoma to the Danish metastatic melanoma da-
tabase and found that 55% of patients would not have met
criteria for inclusion [8]. This results in a level of uncertainty
regarding aspects of the long-term follow-up of metastatic
melanoma survivors. The relative infancy of ICIs in clinical
practice also means there are gaps in our knowledge regarding
general health issues with examples including fertility and the
safety of vaccinations. These uncertainties have the potential
to result in significant distress for patients, caregivers and
other health professional outside the oncology domain.
Though HRQoL and irAEs have previously been
characterised and reported from clinical trials of patients with
metastatic melanoma undergoing treatment with ICIs, no re-
port to date has addressed the metastatic melanoma survivors
specifically. The aim of this study was to examine melanoma
patients’ with metastatic disease, who survived at least 1 year
from commencing an ICI and describe toxicity profiles during
and after ICI therapy, exposure to immunosuppressive agents
and HRQoL in a large single centre in the UK.
Methods
Between May 2017 and August 2017, all patients who
attended the melanoma clinic in the outpatients department
at the Royal Marsden NHS foundation trust and who fulfilled
eligibility criteria as defined below were invited to fill in the
SF-36 questionnaire to assess HRQoL. Patient’s electronic
health records were then accessed to collect clinical data in-
cluding patient demographics, systemic therapies, data regard-
ing prior toxicity (during and after ICI therapy) and treatment
of toxicity and survival data.
Study population
We defined survivors as patients, ≥ 18 years of age, who
achieved a durable response to an ICI and had been
followed-up for a minimum of 12 months from initiation of
ICI without progressive disease, having received at least 1
dose of ipilimumab, nivolumab, pembrolizumab or
ipilimumab + nivolumab in the setting of unresectable stage
III melanoma or metastatic melanoma as defined by the
American joint committee on cancer (AJCC) version 7 staging
system [9].
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‘Durable response to an ICI’ included (1) patients achiev-
ing a response as defined by RECIST criteria (2) patients who
had stable disease (SD) as defined by response evaluation
criteria in solid tumours (RECIST) for > 24 weeks and (3)
patients who were defined as having clinical benefit by their
treating physician from ICI in the absence of a RECIST de-
finable response [10, 11]. We adopted this broad definition of
response in the knowledge that ICIs can result in unique pat-
terns of response and as a result, patients who derive clinical
benefit may not fall within the scope of traditional definitions
of response [12].
Patients with isolated areas of disease progression treated
with surgery or radiotherapy were included if the remainder of
their disease fulfilled our previous definition of response and
when radiotherapy or surgery was completed no less than
6 weeks from the date of the SF-36 form being completed.
We decided to include these patients as they reflect ‘real-
world’ immunotherapy survivors and such patients have the
potential to have prolonged survival despite progressive dis-
ease [13, 14].
We limited the study to patients who are currently under-
going follow-up in the Melanoma unit of a major UK cancer
centre and who were willing and fit to complete the SF-36
questionnaire. Fitness was defined as patients who were phys-
ically capable of filling in the form unaided and those who had
sufficient capacity to complete the questionnaire.
Materials and data collection
Following review by the Trusts’ Research and Development
department, the study was deemed exempt from full review
and approval by a research ethics committee and was consid-
ered to fall under ‘Service Evaluation’ (as per HRA guidance)
(HRA 2016), given the focus was not on sensitive information
and related instead to the treatments received. Aggregated,
non-identifiable data only was collated. It was approved by
the Trust’s Service Evaluation committee (SE), under the
Research and Development department. [15]
Toxicity had been characterised using the immune-related
adverse events (irAE) criteria and graded as per Common
Terminology Criteria for Adverse Events (CTCAE) version
4.0. Objective responses were classified using the RECIST
criteria as described above.
The 36-item short form health survey (SF-36) was used to
assess patient-reported HRQoL (Supplementary data). The
SF-36 is a validated, self-reported questionnaire covering
eight domains of HRQoL: vitality, physical functioning, bodi-
ly pain, general health perceptions, physical role functioning,
emotional role functioning, social role functioning and mental
health [16].
All data regarding toxicity, response and survival was col-
lected up until the date the SF-36 questionnaire was completed
to ensure that toxicity and survival data pertained only to the
period relevant to the HRQoL data.
Data synthesis and statistical analysis
Statistical analysis was performed using SPSS version 24.
Progression-free survival (PFS) was calculated using the date
the last line of systemic therapy was commenced to the date of
progressive disease as defined by RECIST criteria. Median
PFS were calculated using the Kaplan-Meier method.
Differences in SF-36 scores were analysed in pre-planned
subgroups categorised based on age, sex, any grade toxicity,
grade 3 or 4 toxicity, steroid exposure, ICI type and
ipilimumab exposure. Age-based subgroups included the fol-
lowing: adolescents and young adults (AYA) aged 18 to 39 at
time of diagnosis, middle-aged aged 40–65 and the elderly
aged > 65 years. Dichotomized subgroups (e.g. gender, treat-
ment status) were compared using independent t tests.
Subgroups with 3 or more categories (e.g. age, ICI type) were
compared using an ANOVA test. Norm-based scores from 2
sources were compared with HRQoL outcomes from melano-
ma survivors: the British office of national statistics (ONS)
omnibus survey and the Oxford healthy life survey, both from
1992 [17–19]. Demographic data on norm-based sources is
presented in the Supplementary data. Comparison with norm-
based data was performed using one-sample t test.
Results
Between January 2011 and August 2016, 481 patients with
metastatic melanoma were treated with an ICI. Eighty-four
patients (17.5%) met inclusion criteria to be considered part
of the survivor population. Seventy-three patients (87%) were
willing and fit to complete the SF-36 questionnaire. The 11
patients for whom we do not have HRQoL data include 8
patients who were either uncontactable or declined to partake,
2 patients who were inpatients in hospital during the data
collection period (1 was an inpatient for treatment of ICI-
induced toxicity, the other admission was unrelated to ICI
therapy or melanoma) and 1 patient who was not fit to fill in
the SF-36 questionnaire for reasons unrelated to melanoma or
its treatment.
Patient demographics
Patient demographics are presented in Table 1.
At the time of analysis, 29.7% of patients were still actively
undergoing therapy with an ICI. Thirty-nine percent of pa-
tients had stopped treatment due to toxicity. 28.5% of patients
had stopped treatment as they had completed therapy as per
local guidelines (i.e. 4 cycles of ipilimumab, 2 years of PD-1
inhibitor monotherapy or combination ipilimumab and
Support Care Cancer
nivolumab for 4 cycles followed by nivolumab maintenance
up to 2 years). Two percent of patients stopped treatment as it
was their preference to do so. Patients who have stopped ICI
before they completed therapy received a median of
2.1 months (range 0.4–34.6) of systemic therapy.
Survival
Response and responses presented in Table 1. At the time of
analysis, median follow-up was 25 months (95% CI 20.8–
29.1). Forty-six percent of patients had been followed-up for
12–24 months, 18% for 25–36 months and 36% for over
36 months since commencing an ICI. Seventy-six patients
had a response by RECIST criteria translating into an objec-
tive response rate (ORR) of 90%. Eight patients (10%) had SD
as best response.
Twelve patients (14%) had experienced isolated sites of
progression that had been treated with surgery or radiotherapy.
Details of these patients’ best response and treatments are
presented in supplementary data. Median PFS in this group
was 10 months (95% CI 7.7–12.3). Following surgery or ra-
diotherapy, this subgroup has been followed for a median of
13 months (range 4–31) without further intervention for dis-
ease progression.
Toxicity
Rate, class and treatment of irAEs for all patients, patients
exposed to ipilimumab and patients solely exposed to PD-1
inhibitors are presented in Table 2.
Fourteen percent of patients ultimately required therapies
beyond steroids for toxicity including infliximab (n = 5),
mycophenalate (n = 4), vedolizumab (n = 1), sulfasalazine
(n = 1), methotrexate (n = 1), eltrombopag (n = 1), intravenous
immunoglobulins (n = 1) and plasmapheresis (n = 1).
Twelve patients experienced an irAE having discontinued
an ICI. Four such patients developed vitiligo and no other
irAE. Characteristics of the remaining 8 patients are presented
in Table 3.
HRQoL
Table 4 shows scores for the melanoma survivor’s HRQoL
domains as compared with the British ONS omnibus survey
and the Oxford healthy life survey norm-based data [17–19].
The melanoma survivors had statistically significant lower
scores compared with both norm-based datasets in domains
including physical functioning, social functioning, physical
role functioning and general health. There was no statistically
significant difference between the melanoma survivors scores
compared with the norm-based data in domains including
mental health and bodily pain. For emotional role, functioning
and vitality the melanoma survivors had numerically inferior
scores compared with the norm-based data but this only
reached statistical significance in comparison with the
British ONS survey.
In the subgroup analysis statistically significant differences
in physical functioning scores were noted when patients were
categorised based on age (Supplementary data). Scores were
Table 1 Patient demographics, response & survival
Patient demographics
N = 84 %
Median age years (range) 65 (22–86)
Male 54 (64)
Female 30 (36)
Histology
Cutaneous 74 (88)
Mucosal 2 (2)
Unknown 8 (10)
Stage
IIIC Unresectable 1 (1)
M1a 11 (13)
M1b 14 (17)
M1c 58 (69)
Brain metastases 11 (13)
Lines of therapy
1 39 (46)
2 30 (36)
≥ 3 15 (18)
Lines of ICI
1 51 (61)
2 31 (37)
≥ 3 2 (2)
Most recent ICI
Ipilimumab 16 (19)
Pembrolizumab 31 (37)
Nivolumab 18 (21)
Ipilimumab + nivolumab 12 (14)
Blinded clinical triala 7 (8)
Prior systemic therapy
BRAF ± MEK inhibitor 15 (18)
Ipilimumab 32 (38)
Pembrolizumab 1 (1)
Nivolumab 1 (1)
Ipilimumab + nivolumab 1 (1)
Chemotherapy 10 (12)
Other 2 (2)
BRAF mutant 30 (36)
LDH < ULN 60 (71)
LDH ≥ ULN 24 (29)
ECOG at start of ICI
0/1 81 (96)
≥ 2 3 (4)
Autoimmune disease 8 (10)
Responses and survival
CR 36 (43)
PR 40 (48)
OR 76 (90)
SD 8 (10)
PD(B) 13 (15)
ICI immune checkpoint inhibitor, LDH lactate dehydrogenase, CR complete
response, PR partial response, OR objective response, SD stable disease, PD
progressive disease
a Arms: ipilimumab + nivolumab, ipilimumab, nivolumab
b Progressive disease following initial objective response or stable disease
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consistently numerically inferior in elderly patients across all
domains which contribute to the physical component score,
physical role functioning, general health and bodily pain.
These numerical differences resulted in a statistically signifi-
cant difference in the physical component summary between
age groups.
There was considerable variation in scores between pa-
tients depending on which ICI they had received (Fig. 1).
There was a trend towards inferior scores in patients with
previous exposure to ipilimumab but this did not reach statis-
tical significance (Fig. 2). No statistically significant differ-
ence in scores was noted in the remainder of the subgroup
comparisons including sex, treatment status (on/off treat-
ment), any grade toxicity, grade 3 or 4 toxicity and steroid
exposure.
Discussion
To our knowledge, this is the first report to evaluate HRQoL in
metastatic melanoma survivors, showing that survivors have
the potential to encounter impairment in both physical and
mental HRQoL domains and represent a unique population
with specific survivorship needs.
HRQoL has been measured in a number of trials of ICIs in
melanoma. To date, four randomised trials have reported
patient-reported HRQoL beyond the initial 12 weeks of treat-
ment [21]. In Checkmate 066, a randomised phase III trial
comparing nivolumab with chemotherapy, EORTC-QLQ-
C30 scores were maintained throughout follow-up for
nivolumab up to a maximum of 73 weeks. There were statis-
tically significant improvements in EQ-5D scores from base-
line at weeks 7 and 49 and clinically meaningful improve-
ments at weeks 37, 61 and 67 [22]. In Keynote 006, patients
treated with pembrolizumab, irrespective of dose, had smaller
declines in EORTC-QLQ-C30 scores between baseline and
week 12 as compared with ipilimumab (p < 0.001). At week
36, for patients who were still on treatment, EORTC-QLQ-
C30 scores had improved across all treatment arms and were
grossly comparable between treatment groups [23, 24]. In
Checkmate 069, no difference was detected between patients
who were treated with single agent ipilimumab and combina-
tion ipilimumab and nivolumab [25]. In checkmate 067 [26],
an initial non-clinically significant decline in patient report
HRQoL scores was followed by a return to baseline across
all three treatment arms of nivolumab in combination with
ipilimumab, ipilimumab monotherapy and nivolumab mono-
therapy. In each of these four trials, HRQoL data failed to
Table 2 Rates of toxicity in the total survivor cohort, in patients who received treatment with ipilimumab either a monotherapy or in combination with
a PD-1 inhibitor and patients who received a PD-1 inhibitor
Immune-related adverse events
All patients (N = 84)a Ipilimumabb (N = 59) PD-1 inhibitorc (N = 17)
Any grade (%) Grade 3/4 (%) Steroid (%) Immunomodulatory (%) Any grade Grade 3 or 4 Any grade Grade 3 or 4
Total 77 (92) 36 (43) 41 (49) 12 (14) 54 (92) 30 (51) 16 (94) 6 (35)
Colitis 25 (30) 19 (23) 23 (27) 5 (6) 19 (32) 14 (24) 4 (24) 3 (18)
Hepatitis 16 (19) 6 (7) 12 (14) 4 (5) 14 (24) 5 (8) 2 (17) 1 (6)
Msk 23 (27) 4 (5) 5 (6) 2 (2) 17 (29) 4 (7) 5 (29) 0 (0)
Nephritis 3 (4) 3 (4) 3 (4) 1 (1) 2 (3) 2 (3) 1 (6) 1 (6)
Dermatological 59 (70) 10 (12) 26 (31) 0 (0) 36 (61) 7 (19) 14 (82) 2 (12)
Endocrine 26 (31) 6 (7) 6 (7) 0 (0) 21 (36) 5 (8) 5 (29) 1 (6)
Thyroid 17 (20) 0 (0) 0 (0) 0 (0) 13 (22) 0 (0) 4 (24) 0 (0)
Pituitary 6 (7) 2 (2) 2 (2) 0 (0) 6 (10) 2 (2) 0 (0) 0 (0)
Pneumonitis 4 (5) 1 (1) 2 (2) 0 (0) 3 (5) 1 (2) 1 (6) 0 (0)
Neurological 5 (6) 2 (2) 2 (2) 2 (2) 5 (8) 2 (3) 0 (0) 0 (0)
Msk musculoskeletal toxicity arthritis, arthralgia, myalgia
a Rates of immune-related adverse events (irAEs) are presented for patients with any grade toxicity and grade 3 or 4 toxicity. Rates of irAEs that required
steroids for treatment irrespective of grade are presented (match table) as are rates of irAEs that untimely required treatment with an immunomodulatory
agent distinct from steroids (match table)
b Rates of irAEs in patients who received ipilimumab during the course of their cancer therapy
c Rates of irAEs in patients who received a PD-1 monotherapy during the course of their cancer therapy and were never exposed to ipilimumab
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capture patients who discontinued treatment due to toxicity
and these was no comparison with norm-based data.
In our survivor cohort, stratification by age resulted in clin-
ically meaningful and statistically significant differences in
scores in physical health domains. Elderly patients reported
the worst scores. Though recent data would suggest elderly
patients do not demonstrate an increased risk of incurring
irAEs compared with the remainder of the population, there
remains the possibility that they possess reduced physiologi-
cal reserve and thus toxicity may result in a greater impact on
HRQoL [27, 28]. The elderly population is not well represent-
ed in previous reports of HRQoL or the clinical trial setting in
general [27, 29]. Limitations placed on performance status and
organ function mean that elderly patients who do qualify for
inclusion may not be representative of the real-world popula-
tion. Moreover, performance status is a limited tool for eval-
uating elderly patients and does not encompass important pa-
rameters such as frailty comprehensive geriatric assessment
may be more effective during and after therapy and should
be incorporated into future prospective clinical trials [30].
We found no difference in HRQoL in patients who experi-
enced toxicity and those who experienced no toxicity irrespec-
tive of grade and management. This analysis is limited by only
six patients in our cohort not experiencing any toxicity; thus,
these results should be interpreted with caution. A possible
interpretation is that though toxicity is a key contributor to
HRQoL, the patient experience has many dimensions that
are currently not well captured. We observed a trend towards
inferior HRQoL scores in patients exposed to ipilimumab in
domains related to physical functioning. This may be related
to the fact that these patients experienced more grade 3 or 4
toxicity than patients who never received ipilimumab. In our
cohort, hypophysitis (n = 6) and neurotoxicity (n = 5) only
occurred in patients exposed to ipilimumab. Ipilimumab-
induced hypophysitis is frequently a chronic condition requir-
ing life-long steroid replacement [31, 32]. Neurological toxic-
ity has the potential to cause significant morbidity [33].
Toxicities of the same grade can affect HRQoL discordantly
but this is not reflected in current grading systems.
The SF-36 questionnaire is generic and not cancer specific.
This represents a limitation of our study. There are cancer-
specific HRQoL questionnaires available (e.g. EORTC-
QLQ-C30) that has been favoured for use in clinical trials of
ICIs. In terms of being cancer specific, tumour specific, stage
specific and treatment specific, all current HRQoL question-
naires available for use in clinic practice are limited.
Table 3 Immune-related adverse events that occurred in patients who discontinued an immune checkpoint inhibitor
Patients who developed irAEs following discontinuation of immune checkpoint inhibitors
ICI Reason for
discontinuation
Cycles
ICI
irAE before
discontinuation
(grade)
irAE post-
discontinuation
(grade)
Onset irAE post-
discontinuation (months)
Treatment Best
response
Pembrolizumab irAE 13 Colitis (G2)
Rash (G1)
Arthralgia (G3)
Myocarditis (G2) 8.1 No intervention
required,
monitored
SD
Ipilimumab +
nivolumab
irAE 2 Aseptic Meningitis
(G2)
Hepatitis (G3)
Colitis (G3)
Arthralgia (G2) 7.4 Steroids CR
Pembrolizumab Patient
preference
5 Rash (G1)
Hepatitis (G2)
Arthralgia (G1) 5.8 Analgesia PR
Pembrolizumab irAE 19 Colitis (G3)
Arthralgia (G1)
Hepatitis (G3) 3.1 Steroids SD
Pembrolizumab irAE 34 Labyrinthitis (G2)
Hepatitis (G3)
Hypothyroidism
(G2)
Pruritus (G2)
Arthralgia (G3) 4.9 Steroids
Methotrexate
CR
Nivolumab irAE 3 Colitis (G3) Rash (G3) 11.0 Topical steroids CR
Ipilimumab +
nivolumab
irAE 1 Rash + Pruritus (G3)
Hepatitis (G3)
Hypothyroidism
(G2)
Vitiligo (G1)
Arthralgia (G1) 7.9 Analgesia CR
Pembrolizumab irAE 2 Nephritis (G3) Arthralgia (G2)
Rash + Pruritus
(G2)
8
12.6
Intra-articular steroids PR
irAE immune-related adverse event, ICI immune checkpoint inhibitor, SD stable disease, CR complete response, PR partial response, G grade
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Melanoma-specific modules in HRQoL questionnaires are
largely based on long-term sequelae of surgery and though
these are contributory to impaired HRQoL, no survey directly
deals with the long-term complications of metastatic melano-
ma or ICI therapy. A study currently underway in Toronto
aims to develop a tool based on the Functional assessment in
cancer (FACT) tool that is specific to patients undergoing
treatment with immunotherapy (NCT02651831) and would
thus be more sensitive and relevant to metastatic melanoma
survivors. Collection of patient-reported outcomes (PRO) in
research and clinical practice is important as it can facilitate
patient-centred communication, informed decision making,
symptom monitoring and will help to provide patients’ with
the best supportive care. In a recent study, Basch et al. dem-
onstrated a 5-month overall survival benefit for patients with
metastatic solid tumours undergoing PRO monitoring com-
pared with patients receiving standard care (HR 0.83, 95%
CI 0.70–0.99, p = 0.04) [34].
Our study is limited by the usage of SF36 questionnaire
version 1, newer versions are available. The most recent nor-
mative data for the UK population assessed using version 1
was from 1992. This may not be representative of current
populations.Whilst the SF-36 questionnaire includes a mental
health component, it may be useful in future studies to expand
upon this with tools to measure sleep disturbance, distress,
anxiety and fear more comprehensively. Our study is limited
in that it is cross-sectional in design which hinders the deter-
mination of causal associations. There is considerable patient-
to-patient variability in factors that can contribute to impair-
ment in HRQoL in metastatic melanoma survivors. These
may include severity, timing and chronicity of toxicity as well
as quality, timing and durability of response. It is thus not
feasible to capture the many potential facets of HRQoL at a
single time point. Longitudinal data collection from diagnosis
would allow HRQoL to be measured in parallel with key
events in treatment and follow-up and would thus be more
informative.
Conclusions
Clinical trial data to date has limited applicability to the sur-
vivor population defined in this study owing to limited follow-
up time and exclusion of patients who discontinued ICI due to
toxicity before a censoring event. Metastatic melanoma survi-
vors have potentially experienced significant irAEs during
treatment resulting in chronic conditions, exposure to signifi-
cant doses of steroids or exposure to other immunomodulatory
drugs and thus may encounter long-term sequelae to their
cancer and cancer treatment. Our cohort of metastatic mela-
noma survivors demonstrated significant impairments in
physical and mental domains of HRQoL compared with
healthy controls. Within our survivorship population, weTa
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found that elderly patients were a subgroup that had an in-
creased potential for inferior patient-reported HRQoL out-
comes. We strongly support the recognition of the metastatic
melanoma survivors as a distinct population that warrant com-
prehensive longitudinal evaluation with particular focus in
area of HRQoL. Future service planning is required to meet
these patient’s unique survivorship needs.
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